Oncology

The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
The results of an additional secondary endpoint from the phase 3 HERO study evaluating oral relugolix in men with advanced prostate cancer showed that relugolix had a similar rate of castration resistance-free survival compared to intravenous leuprolide acetate in men with metastatic disease through 48 weeks.
[[thumbnail_alt_text]]
Using a 3D model, investigators found a soy-based compound was effective in treating bone cancer.
 
[[thumbnail_alt_text]]
At ESMO 2020, researchers discussed some long-awaited data regarding postoperative radiotherapy used in patients with non-small cell lung cancer following complete resection and after (neo) adjuvant chemotherapy.
[[thumbnail_alt_text]]
New drug application been submitted  for TLX591-CDx (illumet), a radiopharmaceutical product that targets prostate-specific membrane antigen for the imaging of prostate cancer.
[[thumbnail_alt_text]]
Among patients with cervical cancer, there was no significant difference found between the risk of recurrence, local recurrence, or death among individuals who either completed or abandoned a radical uterine procedure following the intraoperative detection of a positive pelvic lymph node.
[[thumbnail_alt_text]]
The FDA has granted fast track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors have high DKK1 expression.
[[thumbnail_alt_text]]
Study shows that upon hospital admission for cancer, many patients already have a high prevalence of malnutrition per Global Leadership Initiative on Malnutrition criteria.
 
[[thumbnail_alt_text]]
The results from a cohort of patients with rare sarcomas in the phase 2 study, presented by professor Jean-Yves Blay, MD, investigated the efficacy and safety of single agent pembrolizumab in rare cancers.
[[thumbnail_alt_text]]
A new study showed that nivolumab was effective in patients with pathogenic exonuclease domain POLE mutated mismatch repair.
[[thumbnail_alt_text]]
The effects of pralsentinib were especially pronounced in treatment-naïve patients with medullary thyroid cancer. 
 
[[thumbnail_alt_text]]
The predictive value provided by T effector and angiogenesis signatures were found to be augmented by Kidney Immune Classification of tumor microenvironments.
[[thumbnail_alt_text]]
Although immune checkpoint inhibitors are not yet approved for first-line therapy in these populations, the new research could lead to a new standard of care.